FRANKFURT Oct 1 German biotech Morphosys
moved a step closer to getting its first antibody drug
onto the market as its licensee, Johnson & Johnson unit
Jenssen, reported positive results from a phase 3 study of
psoriasis drug guselkumab.
Johnson & Johnson said earlier the experimental biotech drug
proved more effective at clearing moderate to severe cases of
the skin condition than a placebo or Abbvie's Humira,
the world's top-selling prescription medicine.
A Morphosys spokesman said on Saturday that guselkumab could
now become its first drug to market, depending on whether and
when Johnson & Johnson makes an application.
Morphosys gets milestone payments during the development
phase and would receive royalties from Johnson & Johnson once it
goes on sale.
It has another drug in phase 3 study with Roche, for
Alzheimer's disease, and one in phase 2 - which in this case is
likely to be the final phase - with Bayer, for
asbestos-related lung cancer.
(Reporting by Georgina Prodhan)